EAM Investors’s Spero Therapeutics SPRO Stock Holding History

EAM Investors’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-218,084	Closed	-$508K	–	367
2025 Q4	$508K	Sell	218,084 -64,361	-23%	-$149K	0.06%	261
2025 Q3	$531K	Buy	282,445 +43,305	+18%	+$95.2K	0.06%	249
2025 Q2	$694K	Buy	+239,140	New	+$344K	0.11%	188

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 374.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM Investors's SPRO Position: Q1 2026 in Review

EAM Investors sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 218,084 shares — an estimated $508K sold.

EAM Investors first reported a position in SPRO in Q2 2025 and held it in 3 quarters. The position peaked at $694K in Q2 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

EAM Investors reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
EAM Investors sold 218,084 Spero Therapeutics shares in Q1 2026, an estimated $508K.
EAM Investors first reported a position in Spero Therapeutics in Q2 2025 and held it in 3 quarters.
EAM Investors's Spero Therapeutics position peaked at $694K in Q2 2025.
50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.